CellPro petitions FDA to deny approval of Baxter's Isolex stem cell separation product.
This article was originally published in The Gray Sheet
Executive Summary
BAXTER 8SOLEX 300 PMA APPROVAL REQUIRES PROOF OF CLINICAL UTILITY, CELLPRO SAYS in a Feb. 6 petition to FDA. Seeking to farestall approval of the Baxter's stem cell separation system, Cellpro states: "It appears that no proof of clinical utility for the Isolex 300 has been presented such as that required of CellPro and that FDA may not require such proof in the PMA for the Isolex 300 system." CellPro markets the Ceprate SC stem cell concentration system.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.